Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on…
A recent study presented at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer found that adding local consolidative therapy (LCT) after dual immunotherapy in metastatic non-small cell lung cancer (NSCLC) did not improve overall or progression-free survival. The Phase III LONESTAR trial randomized 166 immunotherapy-naive patients with metastatic NSCLC to either continue immunotherapy alone or receive LCT followed by immunotherapy.
LCT consisted of radiation to one or more disease sites, and surgery when feasible. At the June 15, 2026 data cutoff, overall survival was 52.8 months with immunotherapy alone compared to 43.2 months with LCT plus immunotherapy (HR 1.14; 95% CI, 0.75--1.74; P = .54), and progression-free survival was 24.3 months versus 31.3 months (HR 0.79; 95% CI, 0.54--1.15; P = .22).
Among patients with oligometastatic disease, overall survival was 75.8 months with immunotherapy alone versus 42 months with LCT plus immunotherapy (median progression-free survival 44.0 months versus 35.7 months, respectively). The addition of LCT after dual checkpoint blockade was feasible, but did not yield improved outcomes.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
